93486
document
Herpes simplex virus vaccine in recurrent herpetic ocular infection . PURPOSE To evaluate the efficacy of an antiherpetic vaccine in recurrent herpetic ocular infections . METHODS Twenty patients with herpes simplex virus 1-related recurrent keratitis/keratouveitis were prospectively enrolled and randomly assigned to receive either a specific vaccination with heat shock-inactivated herpes simplex virus type 1 ( 10 patients ) or to be observed as controls ( 10 patients ) . The number , duration , and anatomic localization of relapses were recorded in all the patients for 12 months before inclusion in the study and for a similar period after the assignment of each subject to vaccine or control group . RESULTS In the vaccine group , we observed a reduction both in the number ( p = 0.016 ) and average duration ( p = 0.050 ) of recurrences , whereas in the control group , no significant change was found comparing a 12-month period before and after inclusion in the study . The comparison between the two groups highlighted a significant reduction in the number ( p = 0.013 ) and average duration ( p = 0.051 ) of relapses in treated subjects , who did not show any significant vaccine-induced side effects . CONCLUSION The use of a vaccination with heat shock-inactivated herpes simplex virus 1 seems to be able to reduce the number and duration of relapses in herpes simplex virus 1-related keratitis/keratouveitis .
93487
Intervention_Pharmacological
Herpes simplex virus vaccine
93488
Intervention_Pharmacological
antiherpetic vaccine
93489
Intervention_Pharmacological
specific vaccination with heat shock-inactivated herpes simplex virus type 1
93490
Intervention_Control
controls
93491
Intervention_Pharmacological
vaccination
93492
Outcome_Other
efficacy
93493
Outcome_Physical
number , duration , and anatomic localization of relapses
93494
Outcome_Other
number
93495
Outcome_Other
average duration
93496
Outcome_Other
recurrences
93497
Outcome_Other
number
93498
Outcome_Other
average duration
93499
Outcome_Other
relapses
93500
Outcome_Adverse-effects
significant vaccine-induced side effects
93501
Outcome_Other
number and duration of relapses
93502
Participant_Condition
recurrent herpetic ocular infection .